

RespireRx Pharmaceuticals Inc.  
Form NT 10-Q  
August 15, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**Notification of Late Filing**

SEC File Number: 1-16467

CUSIP Number: 761227206

(Check one):

Form 10-K    Form 20-F    Form 11-K    Form 10-Q  
 Form 10-D    Form N-SAR    Form N-CSR

For Period Ended: June 30, 2018

Transition Report on Form 10-K    Transition Report on Form 20-F  
 Transition Report on Form 11-K    Transition Report on Form 10-Q  
 Transition Report on Form N-SAR

For the Transition Period Ended:

**Nothing in this form shall be construed to imply that the  
Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  
Not applicable.

**PART I - REGISTRANT INFORMATION**

**RESPIRERX PHARMACEUTICALS INC.**

Full Name of Registrant

**126 Valley Road, Suite C**

Address of Principal Executive Office (*Street and Number*)

**Glen Rock, New Jersey 07452**

(City, State and Zip Code)

**PART II - RULES 12B-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [ ]

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;  
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the
- (b) prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III - NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

RespireRx Pharmaceuticals Inc. (the "Registrant") was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended June 30, 2018 (the "Quarterly Report") by the August 14, 2018 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements. Due to limited financial and other resources, the Registrant was not able to commence its quarterly discussions with its accountants in a timely fashion. As a result, the Registrant is still in the process of preparing disclosure and validating information needed to complete the Quarterly Report and requires additional time to complete the Quarterly Report. The Registrant is working diligently to complete preparation of the Quarterly Report and intends to file a complete Quarterly Report as soon as practicable, but does not expect to make that filing within the extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

**PART IV - OTHER INFORMATION**

Name and telephone number of person to contact in regard to this notification:

**Jeff E. Margolis (201) 444-4947**  
(Name) (Area Code) (Telephone Number)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes  No

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

RespireRx Pharmaceuticals Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 15, 2018 **RespireRx Pharmaceuticals Inc.**

By: */s/ Jeff E. Margolis*

Jeff E. Margolis

Senior Vice President, Chief Financial Officer,

Treasurer and Secretary

